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pattern of Altered plasma 
elemental phosphorus, Calcium, 
Zinc, and Iron in Alzheimer’s 
Disease
Azhaar Ashraf1, Hagen stosnach2, Harold G. parkes3, Abdul Hye4,5, John powell6, for the 
AddNeuroMed consortium* & po-Wah so  1
Metal/mineral dyshomeostasis has been implicated in the development of Alzheimer’s disease (AD). 
The aim of the study was to investigate the difference in absolute and percentage levels of plasma 
phosphorus, calcium, iron, zinc, copper, selenium in cognitively normal (CN) and AD subjects. total 
reflection X-ray fluorescence (TXRF) spectroscopy was used to detect plasma metals/minerals in CN 
and AD subjects (n = 44 per group). TXRF detected significantly increased plasma levels of phosphorus 
(p = 1.33 × 10−12) and calcium (p = 0.025) in AD compared to CN subjects, with higher phosphorus/
calcium (p = 2.55 × 10−14) ratio in the former. percentage concentrations calculated for phosphorus, 
calcium, iron, zinc, copper, selenium by dividing the concentration of each element by the total 
concentration of these elements and multiplying by 100%, demonstrated phosphorus was higher in AD 
compared to CN subjects, while calcium, iron, zinc, copper and selenium were lower in AD subjects, with 
area under the curves as high as 0.937 (p = 6 × 10−5) computed from receiver operating curves. With 
exclusion of high levels of phosphorus and calcium from percentage calculations, iron levels remained 
low in AD whereas zinc was higher in AD, and copper and selenium levels were similar. We demonstrate 
altered distribution of elements in the plasma of AD subjects with high interdependencies between 
elemental levels and propose the potential of TXRF measurements for disease monitoring.
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly population with a predicted inci-
dence of 115.4 million cases by 2050. It is characterised by pathological inclusions of extracellular ß-amyloid (Aß) 
plaques and intracellular neurofibrillary tangles1. With the lack of a cure, and only mildly effective symptomatic 
treatments at best, there is a great impetus to understand this incurable dementia. Metal dyshomeostasis (particu-
larly iron, zinc and copper) has recently been implicated in the development of AD2. These metals can accentuate 
plaque formation and affect tau hyperphosphorylation albeit to a lesser extent. Aberrant homeostasis of these 
transition elements and enhancement of protein aggregation and detrimental interactions with protein aggregates 
can generate oxidative stress contributing to neurodegeneration in AD2. Also, there has been considerable debate 
regarding the contribution of aluminium to AD. A common feature of neurodegenerative diseases such as AD are 
changes in ratios of various metals3.
Dyshomeostasis of other micronutrients such as calcium is also evident in the AD brain4. Circulating calcium 
and phosphorus are regulated by parathyroid hormone (PTH). In secondary hyperthyroidism, PTH levels are 
high, alongside normal to low calcium and a concurrent decrease in vitamin D levels5. High serum phosphate has 
been associated with increased incidence of dementia6 as well as changes in phosphorus/calcium ratios7.
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AD has a well-known prodromal stage1 which provides a therapeutic window when pathological processes 
are still responsive to treatment. However, determining this prodromal stage is difficult and drives much of the 
current biomarker research. While cerebrospinal fluid (CSF) Aß, phosphorylated and total-tau are used as bio-
markers of AD1, their use to monitor the prodromal phase is debatable and impractical. CSF collection is by 
lumbar puncture, an uncomfortable sampling method for the individual, especially the elderly and associated 
with morbidity, and while used to assist diagnosis, it is inappropriate for screening or repeat sampling for disease 
monitoring. Thus, there is the impetus towards peripheral-based biomarkers such as those in plasma which can 
be readily collected and repeatedly, if necessary.
Investigators have tested whether alterations of brain metals and other elements are peripherally reflected to 
potentially aid in diagnosis and disease monitoring5,6,8. No consensus has been obtained with regards to whether 
the peripheral concentrations of various elements are modulated in AD owing to discrepant findings. This may 
be attributable to plasma levels, being not only affected by AD pathogenesis, but also affected by diet, nutri-
tional status, sex, age, etc. Additionally, the analytical method used may impact the measurements, some methods 
requiring sample preparation, the complexity varying between analysis methods; whether free or bound elements 
or their isotopes are measured, etc. A few studies do report analysis of a panel of metals by inductively-coupled 
plasma mass spectroscopy (ICP-MS) showing differences between cognitively normal (CN), mild cognitive 
impairment (MCI) and AD2,3.
In this study, we quantify the plasma elemental concentrations of phosphorus, calcium, iron, copper, sele-
nium and zinc using total reflection X-ray fluorescence (TXRF) spectrometry in age- and sex-matched AD and 
cognitively normal (CN) individuals. TXRF measures all the isotopes of an element and detection limits can be 
comparable to atomic absorption spectroscopy (AAS), inductively coupled plasma optical emission spectroscopy 
(ICP-OES) or ICP-MS9. Matrix effects are minimised enabling higher sensitivity and low detection limits in the 
order of parts per billion. A key advantage of TXRF is the relatively simple sample preparation required compared 
to other techniques, contributing to its robust nature, with errors relating to pipetting small volumes rather than 
extraction efficiency of metals from biofluids or matrix effects. Other advantages include smaller analytical vol-
umes needed (as low as 10 µl)10; simple quantification using an internal standard; and simultaneous multi-element 
trace analysis without bias towards expected elemental compositions11,12. We aim to determine whether plasma 
phosphorus, calcium, iron, copper, selenium and zinc; and phosphorus/calcium ratio, differentiates between CN 
and AD individuals and may be putative peripheral biomarkers of AD. This is the first study that we are aware 
of, applying TXRF to the analysis of blood for biomarker discovery in AD, and proposes a possible role of TXRF 
instrument in the clinical chemistry laboratory.
Materials and Methods
subjects. Plasma samples from AD and CN controls were selected from the AddNeuroMed cohort13. 
Informed consent was obtained from all participants according to the Declaration of Helsinki (1991), and proto-
cols and procedures were approved by The Joint South London and Maudsley and the Institute of Psychiatry NHS 
Research Ethics Committee. The diagnosis of probable AD was made according to the Diagnostic and Statistical 
Manual for Mental Diagnosis, fourth edition and National Institute of Neurological, Communicative Disorders 
and Stroke–AD and Related Disorders Association criteria, with Mini-Mental State Examination (MMSE) score 
of <24 for cognition. The APOE single nucleotide polymorphisms (SNPs) rs429358 and rs7412 were genotyped 
using Taqman SNP genotyping assays (determined by allelic discrimination assays based on fluorogenic 50 
nuclease activity) and the allele inferred. In total, we examined 88 subjects: n = 44, AD; n = 44, CN; age- and 
sex-matched.
Blood Collection. Blood collection was performed in the morning after an overnight fast. Venous blood was 
collected into lithium heparin tubes (Becton and Dickinson) and centrifuged. Plasma was separated, frozen and 
stored at −80 °C prior to TXRF analysis.
TXRF of Plasma. Plasma were thawed and 20 μl of a gallium standard solution (2 mg/l, Kraft GmbH, 
Germany) was added to each sample volume of 20 µl. After thorough mixing, 10 μl of each solution was put onto 
TXRF quartz glass carriers and air dried: duplicates of each sample were performed. TXRF data was collected 
over 1000 s on a TXRF spectrometer (S2 PICOFOX, Bruker Nano GmbH, Germany) with a molybdenum tube 
excitation source operating at 50 kV/600 μA. TXRF spectra were inspected, and all elements identified, prior to 
deconvolution of the spectra using the PICOFOXTM software. Elemental concentrations of phosphorus, calcium, 
iron, copper, zinc and selenium were calculated by reference to the gallium standard in each sample.
Accuracy of the TXRF measurements was validated by analysing two certified reference samples (SeronormTM 
serum levels 1 and 2, Sero, Norway). The lower limit of detection (with three-sigma detection) for an element e 
(LLDe) was calculated according to the following equation:
=LLD 3C A /Ae e e bg
where Ce is the elemental concentration, and Ae and Abg are the areas of the fluorescence peak for element e and 
the background subjacent to the fluorescence peak for e, respectively. The measurement time for the calculation 
of LLDe was also 1000 s, the same as for the plasma samples. Each Seronorm™ standard was measured ten times.
The method detection limit (MDL) was also calculated. The MDL is defined as ‘the minimum concentration 
of a substance that can be measured and reported with 99% confidence that the analyte concentration is greater 
than zero and is determined from analysis of a sample in a given matrix containing the analyte’. The MDLe for 
an element e was calculated (according to the U.S. Environmental Protection Agency, Title 40 Code of Federal 
Regulations Part 136, Appendix B, revision 1.11) using the following equation:
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= = .=MDL t SD 2 861 SDne ( 1, 99%)
where t(n=1,99%) is the students’ t-value for a 99% confidence level and a standard deviation (SD) with n − 1 degrees 
of freedom.
statistical Analysis. Data analysis was performed using SPSS IBM version 24.0. Normal distribution 
was checked graphically using box plots, histogram, Q-Q plots, stem and leaf diagrams and numerically using 
Shapiro-Wilk’s test. The following variables were square-root transformed to normality: phosphorus, copper, sele-
nium; and calcium, iron and zinc were log transformed. Analysis of Co-Variance (ANCOVA) was used to determine 
elemental differences between the CN and AD groups with co-variates: diagnosis, sex, APOE status, diagnosis x sex, 
diagnosis x APOE, diagnosis x sex x APOE and sex x APOE. A p-value of ≤ 0.05 was considered significant. The 
phosphorus/calcium ratio was also calculated as in previous studies and underwent ANCOVA testing.
Absolute concentrations of metals/elements in serum have been shown to be highly variable14 and possi-
bly interdependent. Thus, partial correlation analysis adjusted for age, sex, APOEε4 and diagnosis status was 
performed to determine interdependencies between the elements: phosphorus, calcium, iron, copper, zinc and 
selenium. A p-value of ≤ 0.05 was considered significant. Percentage concentrations were also calculated for 
phosphorus, calcium, iron, zinc, copper, selenium by dividing the concentration of each element by the total 
concentration of these elements and multiplying by 100%. As percentages of the elements were not normally 
distributed, the Mann-Whitney U test was performed to determine differences between the CN and AD, with 
p-value ≤ 0.05 being considered significant. As phosphorus and calcium levels were comparatively much higher 
than that for iron, zinc, copper and selenium, percentages for the latter elements were re-calculated with the 
exclusion of phosphorus and calcium and again tested for significance.
Binary logistic regression model adjusted for age, sex and APOEε4 status was used to calculate predictive 
probabilities of elemental percentages. These standardized predictive probabilities were then used to calculate 
the receiver-operator curves (ROC) and areas under the curve (AUC). For regression models, we ensured normal 
distribution of residuals and absence of multi-collinearity. A p-value of ≤ 0.05 was considered significant.
Results
Demographics, clinical data, and plasma elemental concentrations for CN and AD groups are shown in Table 1 
and a dot plot of the elemental concentrations shown in Fig. 1. TXRF measurements of elemental concentrations 
were validated using Seronorm™ Levels 1 and 2 (Table 2). Of the elements studied, selenium had the lowest abun-
dance in the plasma and levels as low as 0.012 mg/l could be measured.
Absolute plasma elemental Concentrations and Interdependencies. Plasma phosphorus 
(p = 1.33 × 10−12) and calcium (p = 0.025) were significantly higher in AD compared to CN (Tables 1 and 3). 
Further, a higher phosphorus/calcium (p = 2.55 × 10−14) ratio was observed in AD patients (Tables 1 and 3). 
Absolute plasma concentrations of iron, zinc, copper and selenium were similar between the groups (Table 1). By 
partial correlation analysis, plasma levels of elemental phosphorus, calcium, iron, zinc, copper and selenium were 
shown to be strongly interdependent (Fig. 2). Hence, further statistical analysis between the CN and AD groups 
was performed on percentages of these elements.
percentages of plasma elemental Concentrations. Of the six elements quantified, the percent-
ages of phosphorus and calcium were much higher in the plasma than that for iron, zinc, copper and selenium 
(Table 4). Further, the percentage of phosphorus in the plasma was higher in AD than CN (p = 7.55 × 10−11, 
Cognitively Normal Alzheimer’s Disease p-value
n 44 44 —
Age (years) 76.0 ± 5.3 77.5 ± 6.2 0.13
Females (n, %) 24 (53) 24 (57) 0.78
MMSE 28.90 ± 1.30 20.80 ± 4.60 1.11 × 10−17
CDR total score 0.05 ± 0.10 1.10 ± 0.60 6.30 × 10−20
APOEε4-positive (n, %) 17 (38) 24 (57) 0.04
Phosphorus@ (mg/l) 47.71 ± 31.89 105.02 ± 40.50 1.33 × 10−12
Calcium# (mg/l) 78.44 ± 34.69 94.64 ± 39.83 0.03
Iron# (mg/l) 1.51 ± 1.07 1.30 ± 0.76 0.55
Copper@ (mg/l) 1.08 ± 0.42 1.02 ± 0.44 0.70
Selenium@ (mg/l) 0.112 ± 0.049 0.106 ± 0.067 0.61
Zinc# (mg/l) 0.79 ± 0.44 1.02 ± 0.64 0.93
Phosphorus/Calcium 0.60 ± 0.28 1.14 ± 0.28 0.30
Table 1. Demographics, Mini-mental state examination (MMSE) and Clinical dementia rating (CDR) scores, 
and Total Reflection X-Ray Fluorescence (TXRF) plasma elemental measurements. Values are mean ± standard 
deviation. ANCOVA was performed of the transformed data adjusted for age, sex, APOE status and diagnosis 
and differences considered significant if p < 0.05. Data transformed to normality by square-root@ and log 
transformation#.
www.nature.com/scientificreports/
4Scientific RepoRts | (2019) 9:3147 | https://doi.org/10.1038/s41598-018-37431-8
Table 4), whereas the percentage of calcium (p = 6.04 × 10−11), iron (9.85 × 10−9), zinc (p = 1.20 × 10−5), copper 
(p = 1.63 × 10−10) and selenium (p = 9.22 × 10−12) were lower in AD (Table 4). As phosphorus and calcium were 
at much higher levels than the other elements, their inclusion for the calculation of elemental percentages could 
potentially bias the analysis. Thus, the analysis was repeated but percentages of iron, zinc, copper and selenium 
were re-calculated with the exclusion of phosphorus and calcium. Again, plasma iron was significantly lower in 
the AD patients compared to CN subjects (Table 4; p = 0.028). However, zinc was higher in AD than CN (Table 4; 
p = 1.74 × 10−4), whereas plasma copper and selenium levels were comparable between CN and AD.
Logistic Regression Analysis. ROC based on the binary logistic regression model were used to determine 
the sensitivity of percentages of the elements in the plasma to predict CN or AD. The AUC of the base model 
(age, sex and APOEε4 genotype) was 0.643 (Fig. 3A), which was considerably improved by the addition of phos-
phorus (AUC = 0.930, p = 1.2 × 10−5; Fig. 3B) or calcium (AUC = 0.927, p = 1.6 × 10−5, Fig. 3C). The AUC also 
improved with addition of iron, copper or selenium (AUCs: 0.863, 0.912 and 0.937; p = 1.96 × 10−3, 6.00 × 10−5 
and 6.00 × 10−5, respectively; Figs 2E,F and 3D). Zinc had no effect on the base model AUC (p = 0.120, Fig. 3G), 
while the phosphorus/calcium ratio significantly improved the AUC (0.926, p = 2 × 10−5, Fig. 3H).
Figure 1. Dot plot of Total Reflectance X-Ray Fluorescence (TXRF) measurements of elements in plasma from 
cognitively normal (CN) and Alzheimer’s Disease (AD) subjects. P-values for each element and the phosphorus/
calcium ratio are shown following normalisation of data and ANCOVA testing (see Table 1).
Element
Seronorm™ 1 Seronorm™ 2
Reference~ TXRF LLD MDL Reference~ TXRF LLD MDL
Phosphorus 70.0 ± 3.0 71.0 ± 3.5 1.8 10.0 110 ± 22 127.0 ± 5.5 1.9 30
Calcium 94.2 ± 4.4 90.0 ± 3.7 0.07 5.5 119 ± 24 123.0 ± 4.7 0.07 12
Iron 1.39 ± 0.08 1.41 ± 0.07 0.02 0.06 2.15 ± 0.43 2.07 ± 0.07 0.02 0.06
Copper 1.69 ± 0.08 1.74 ± 0.08 0.01 0.05 1.93 ± 0.39 1.88 ± 0.07 0.01 0.05
Selenium 0.107 ± 0.007 0.116 ± 0.009 0.007 0.012 0.136 ± 0.041 0.127 ± 0.012 0.007 0.006
Zinc 1.74 ± 0.07 1.72 ± 0.07 0.01 0.06 1.53 ± 0.31 1.71 ± 0.08 0.01 0.06
Table 2. Validation of Total Reflectance X-Ray Fluorescence (TXRF) measurements of plasma elemental 
concentrations using Seronorm™ Level 1 and 2 standards, alongside lower limit of detection (LLD, 3σ 
detection) and method detection limit (MDL) for each element. Values are mean ± standard deviation (mg/l). 
[~Reference value measured by inductive-coupled plasma-sector field mass spectrometry].
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Discussion
We report a pattern of increased percentage of phosphorus but decreased calcium, iron, copper, zinc and sele-
nium in the plasma from AD subjects compared to CN. High absolute levels of phosphorus and calcium were best 
able to discriminate between demented and non-demented cases, especially phosphorus. We demonstrate strong 
interdependencies between plasma levels of phosphorus, calcium, iron, copper, selenium and zinc. These findings 
extend and support previous studies that suggest the involvement of metal dyshomeostasis in AD but that there 
appears an even greater contribution from those systems regulating phosphorus and calcium metabolism.
Age Diagnosis Sex APOE Diagnosis*Sex Diagnosis*APOE
Diagnosis 
*Sex 
*APOE
Sex 
*APOE
MMSE 0.005 1.11 × 10−17 0.071 0.490 0.023 0.292 0.443 0.345
Phosphorous@ 0.185 1.33 × 10−12 0.484 0.205 0.126 0.207 0.201 0.367
Calcium# 0.348 0.025 0.216 0.396 0.648 0.983 0.693 0.641
Iron# 0.554 0.213 0.305 0.200 0.683 0.619 0.684 0.289
Copper@ 0.703 0.607 0.269 0.220 0.523 0.969 0.235 0.900
Selenium@ 0.605 0.737 0.511 0.492 0.863 0.086 0.167 0.159
Zinc# 0.928 0.125 0.994 0.739 0.347 0.906 0.787 0.590
Phosphorus/Calcium 0.296 2.55 × 10−14 0.904 0.553 0.135 0.085 0.351 0.294
Table 3. ANCOVA was performed of the transformed data adjusted for age, sex, APOE status and diagnosis 
and differences considered significant if p < 0.05. Data transformed to normality by square-root@ and log 
transformation#.
Figure 2. Heat map of partial correlations between the phosphorus, calcium, iron, copper, selenium and zinc 
(of the transformed data), controlling for age, sex, APOE status and diagnosis. (The correlation coefficient, r, is 
the top value in the matrix cell with the p-value below.) Phosphorus, copper and selenium have been square-
root transformed, while calcium, iron and zinc were log-transformed.
Elemental Percentage @Elemental Percentage
CN AD p-value CN AD p-value
Phosphorus 34.74 ± 11.26 51.62 ± 6.50 7.55 × 10−11 NA NA NA
Calcium 62.40 ± 10.68 46.68 ± 6.19 6.04 × 10−11 NA NA NA
Iron 1.21 ± 0.48 0.64 ± 0.23 9.85 × 10−9 41.60 ± 8.36 37.40 ± 8.64 0.03
Copper 0.91 ± 0.36 0.51 ± 0.12 1.63 × 10−10 32.00 ± 6.39 30.40 ± 5.42 0.37
Selenium 0.09 ± 0.03 0.05 ± 0.01 9.22 × 10−12 3.37 ± 0.99 3.13 ± 1.04 0.35
Zinc 0.64 ± 0.18 0.51 ± 0.30 1.20 × 10−5 23.10 ± 4.52 29.00 ± 8.79 1.73 × 10−4
Table 4. Non-parametric test (Mann-Whitney U test) was performed to determine differences between plasma 
levels of elements between cognitively normal (CN) and AD subjects, with elements expressed as a percentage 
of all the elements but also with @exclusion of phosphorus and calcium. A p < 0.05 was considered significant. 
(NA, not applicable).
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The higher plasma phosphorus (both absolute and percentage levels) observed in AD patients in our study is 
consistent with a recent study showing high serum phosphate was associated with increased risk of AD, vascu-
lar dementia and Lewy Body dementia6. Binary logistic regression modelling demonstrated the importance of 
phosphorus to distinguishing AD from CN subjects. Dementia is a recognised comorbidity with chronic kidney 
disease in which serum phosphate is often raised15. Accompanying elevated plasma phosphate is an increase in 
fibroblast growth factor-23 (FGF-23) which itself is associated with cerebral small vessel disease that strongly 
drives cognitive decline and dementia16. Serum phosphate and FGF-23 can be increased by increasing dietary 
intake17; food, especially processed foods, commonly contain phosphate additives18. High phosphorus intake itself 
is also associated with increased cardiovascular risk and mortality19. Interestingly, high serum phosphate has been 
shown to be independently associated with the pro-inflammatory cytokine, IL-620, with high phosphate intake 
inducing inflammation and increased serum TNFα in uremic rats21. Increased peripheral pro-inflammatory 
cytokines is characteristic of AD22 and high circulating phosphate may contribute to the increased inflammatory 
milieu in AD. Whether reducing phosphorus intake and lowering blood phosphate levels attenuates demen-
tia remains to be investigated. Note that we have assumed that the elemental phosphorus measured by TXRF 
is mainly from phosphate, which is the usual form of phosphorus assessed by conventional clinical chemistry 
methods.
Increased plasma calcium in AD is concomitant with the increased phosphorus in our study, although 
decreased if expressed as a percentage of the panel of six elements which illustrates the difficulties in interpret-
ing elemental concentrations. Alternatively, expressing the ratio of phosphorus/calcium may aid interpretation, 
with the ratio being higher in AD than CN. Calcium dyshomeostasis has been consistently implicated in AD23. 
Serum calcium levels are modulated by APOE, appearing to increase neuronal calcium influx to increase Aβ and 
associated with worse cognitive function in APOEε4 carriers, but this interaction is lost in APOEε2 carriers24. 
However, calcium changes can be mediated by non-APOE mechanisms. Plasma calcium levels are regulated by 
vitamin D and PTH. Hyperparathyroidism, characterised by elevated PTH, with high or elevated calcium, usually 
with low vitamin D levels, has been associated with impaired cognitive function and dementia25. Elevated blood 
phosphate and calcitriol (synthesized from vitamin D) deficiency may increase PTH secretion26 and explain the 
higher plasma calcium in AD observed in this study.
Lower percentage of plasma selenium in AD in this study is, consistent with previous studies. However, abso-
lute levels were comparable between AD and CN or when comparing percentages calculated with exclusion of 
phosphorus and calcium, and explains the lack of consistency in alterations in blood selenium levels in AD27. 
Inclusion of selenium as a percentage of all elements studied gives the highest sensitivity and specificity to AD in 
this study. Selenium is often a cofactor in antioxidant molecules/pathways and the low peripheral levels in AD 
observed may contribute to increased susceptibility to oxidative stress, a major aspect of AD pathology. Indeed, 
a selenium and/or vitamin E supplementation trial had been undertaken to determine if supplementation can 
attenuate AD28. AD was not attenuated/prevented by selenium supplementation, but the study was underpow-
ered, only involved men, and supplementation was of relatively short duration. However, selenium status has been 
shown to be determined by local geology and if sufficient, selenium has little impact on AD29.
Zinc has been reported to be decreased or unchanged in the serum and in CSF of AD patients30 but decreased 
serum zinc has been proposed to be due to ageing rather than AD31. Additionally, a recent ICP-MS study 
Figure 3. Receiver operating curves (ROC) of binary logistic regression modelling of cognitively normal (CN) 
and Alzheimer’s Disease (AD) subjects. Base model includes age, sex, APOEε4 genotype (A) and addition of 
percentage phosphorus (B); calcium (C); iron (D), copper (E), selenium (F) and zinc (G), and phosphorus/
calcium (H). AUC – Area under the curve.
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suggested serum zinc is increased with subjective memory complaint but decreased in MCI and AD14. Absolute 
zinc levels were comparable between CN and AD in this study but was significantly lower in the latter when nor-
malised to the total concentrations of the panel of six elements. Conversely, zinc was higher in AD than CN if the 
percentage was calculated with the exclusion of phosphorus and calcium. The strong interdependences observed 
here and in other studies3,32 may contribute to the disparate findings in studies which usually only measure abso-
lute levels of one or two metals. By considering panels of elements/metals rather than one or two of them, varia-
tions in exposure and nutrition may be accounted for somewhat (see below).
Anemia and attenuated hemoglobin levels are associated with an approximately two-fold increased risk for 
developing AD, establishing anemia as a risk factor for cognitive loss8,33. Significantly lower percentage plasma 
iron observed in the present study could arise due to deficient iron-loading into transferrin8,34 by dysfunctional 
ceruloplasmin, a ferroxidase that facilitates iron loading into transferrin35, reported in serum and CSF of AD 
(and PD) subjects36. Low peripheral iron levels may compromise hemoglobin production, leading to a significant 
decline in hemoglobin levels in AD8. Previous evidence has implicated transferrin and its receptor alleles as risk 
factors for AD37.
Copper dyshomeostasis has been implicated in AD, with reduced plasma copper and ceruloplasmin levels 
correlated to impaired cognitive performance in AD subjects38. Overexpression of APP in Tg2576 mice lead to 
copper deficiency, associated with impaired superoxide dismutase and ceruloplasmin prior to the appearance of 
amyloid neuropathology39. Copper supplementation has been proposed to be beneficial in AD by normalizing 
reduction of plasma copper38. In this study, we show that the percentage of copper is lower in AD than CN. 
However, absolute copper levels and copper percentages with the exclusion of phosphorus and calcium, were 
similar in CN and AD and consistent with larger published studies40.
Ageing is associated with a chronic inflammatory state, both peripherally and centrally and even more so, 
in AD21,22. Inflammation induces hepcidin secretion from the liver which promotes ferroportin degradation to 
increase iron retention in enterocytes and peripheral macrophages41,42. Thus, peripheral inflammation in AD 
may explain the decreased percentage of circulating iron levels observed in this study. Iron deficiency directly 
stimulates bone production and cleavage of FGF23 as well as via enhanced renal erythropoietin production17. 
Elevated peripheral inflammatory cytokines will also stimulate of FGF23 production and cleavage16 and as men-
tioned above, elevated FGF23 levels are associated with increased risks of cardiovascular disease and cognitive 
impairment/dementia.
Further research is required to understand the true meaning of plasma values in the context of AD. 
Considering the variability in exposure to environmental and/or nutritional factors (particularly in the con-
text of malnourishment) which are significant variables, it is difficult to make precise conclusions on the liaison 
between the elements measured and AD. We and others2,3, have attempted to account for environmental factors 
and/or nutritional status to some degree by normalising values to a panel of elements. Changes in peripheral 
circulating levels of elements may reflect decreased or increased body intake/absorption and/or re-distribution 
between cellular and tissue compartments, e.g., increased brain accumulation. Our dataset does not include 
information on dietary intake of the various elements analysed in the study or their excretion from the body; 
any co-morbidities; and/or levels of proteins that integrate the metabolism of the elements measured. However, 
our cohort was age-matched, and sex balanced. There is also the concern that plasma mineral and metal meas-
urements may reflect weight loss and malnutrition, common in AD, particularly at end stage disease. Thus, our 
patient cohort comprise only mild-moderate AD (MMSE ~ 20), where only 3% of individual would be expected to 
be malnourished43. We are unable to establish causality in this observational study but propose pathways worthy 
of further investigation in AD.
In the present study, we demonstrate altered distribution of minerals and metals in the plasma of AD and 
considerable interdependency in their circulating levels. Future studies should take the nutritional and environ-
mental elemental exposure status into account to more accurately reflect the association between the elements 
and AD. We propose the plasma signature of high absolute levels of phosphorus and calcium, a high phosphorus/
calcium ratio with a low percentage of iron may be indicative of cognitive impairment and/or AD. Further inves-
tigations are needed to determine if this pattern is common to dementia, useful for assessing the prodromal stage 
of AD, and/or monitoring AD progression.
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